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STATEMENT OF TRANSLATIONAL RELEVANCE
ABL tyrosine kinase inhibitors (TKI) are employed for chronic myeloid leukemia (CML) treatment and induce durable remissions in the majority of patients. However, resistant disease and persistence of BCR-ABL1-independent leukemia stem and progenitor cells remain clinical challenges.
Furthermore, ABL-TKI are associated with the risk of severe side effects in long term use. Therefore, novel therapeutic strategies are warranted to target persisting stem cells and resistant clones alone or in combination with ABL-TKI.
We demonstrate here the activity of an Axl inhibitor, BGB324, against TKI-sensitive and -resistant BCR-ABL1 positive cells, including T315I-mutated and ponatinib-resistant primary cells. Inhibition of Axl with BGB324 exerted therapeutic effects in complementary T315I-mutated and ponatinib-resistant preclinical mouse models. BGB324 was well-tolerated in Phase 1 clinical trials in healthy volunteers and AML patients (BGBC001, BGBC003 ongoing). Thus our findings can be rapidly translated to the clinics and BGB324 holds promise to improve treatment of CML patients.
INTRODUCTION
Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome resulting from a reciprocal translocation between the chromosomes 9 and 22, which is present at least in 90% of CML cases (1, 2) . This translocation results in BCR-ABL1, an oncogenic fusion protein. BCR-ABL1 is a constitutively activated tyrosine kinase (TK) triggering several pro-survival signaling pathways in CML cells, conferring a proliferative advantage and resistance to apoptosis (3, 4) . Therefore, BCR-ABL tyrosine kinase inhibitors (TKI) were developed, which became the standard-of-care in CML. Today, five different BCR-ABL TKI, imatinib, dasatinib, nilotinib, bosutinib and ponatinib are approved in different clinical scenarios leading to durable responses in most CML patients treated (5) (6) (7) (8) . Nevertheless, resistance to BCR-ABL TKI represents a clinical challenge in a substantial fraction of CML patients. Well-described mechanisms of resistance include mutations in the BCR-ABL1 tyrosine kinase domain, including the gate-keeper T315I mutation mediating resistance to all approved agents with the exception of ponatinib.
Furthermore, BCR-ABL1 independent mechanisms of CML stem cell persistence and resistance hamper treatment of CML patients (9) (10) (11) .
Furthermore, BCR-ABL TKI are associated with side effects in long-term use (12, 13) . Despite the dramatic clinical progress upon treatment with these drugs and the possibility to discontinue treatment in approximately 50% of patients (14) , allogeneic stem cell transplantation represents the only proven long-term curative treatment (15) (16) (17) . Therefore, novel therapeutic strategies are warranted to target persisting stem cells and resistant clones alone or in combination with BCR-ABL TKI. 
MATERIAL AND METHODS

Animals
Six to 8 week old female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were purchased from Jackson laboratory (Bar Harbor, ME, USA). All animal experiments were carried out in concordance with the institutional guidelines for the welfare of animals in experimental neoplasia and were approved by the local licensing authority (Behörde für Soziales, Gesundheit, Familie, Verbraucherschutz; Amt für Gesundheit und Verbraucherschutz, Hamburg, Germany, project number G53/12).
Patient samples
Axl expression levels were analyzed in bone marrow MNCs from healthy donors and from patients with newly diagnosed CML at the University Hospital recommendations were analysed at the same timepoint. Patients were treated with imatinib (n=11) or nilotinib (n=6). Four patients showed mutations within the BCR-ABL1 kinase domain (G250E, E255K, T315I, F359V, n=1 each). These analyses were approved by the local ethics committee. All studies with human samples were carried out in accordance with the declaration of Helsinki.
Isolation and culture of MNC and CD34 + cells
MNCs were isolated from blood or bone marrow using Ficoll-Paque. Primitive 
Drug treatment conditions
Treatments were carried out in serum-free medium containing cytokines with different concentrations of BGB324. Imatinib was used at different concentrations alone or in combination with BGB324 for 3 or 48 h as indicated in the figure legends. In the combinatory experiment the IC 50 dose level of 1.5 µM BGB324 and 500 nM imatinib, respectively were used. Primary MNCs or CD34 + isolated from healthy donors or CML cells were treated as specified.
After 48 h, cell viability was assessed by WST-1 assay (Roche Applied Science, Mannheim, Germany). Primary cells from a BCR-ABL TKI-resistant patient and a patient with a BCR-ABL1-T315I mutation were treated for 72 h with 100 nM ponatinib, 150 nM dasatinib and 3 µM of BGB324 prior to apoptosis and colony assays.
Flow cytometry
Proliferation and apoptosis levels were measured by flow cytometry using BrdU incorporation and 7-AAD staining (to exclude dead cells) (BD, Heidelberg, Germany), and AnnexinV-FITC/propidium iodide, respectively. Events were captured using BD FACS Calibur.
Colony forming assay
Clonogenic potential of cells surviving in vitro drug treatments was determined by colony forming cell assay whereby cells were aliquoted in duplicate in semisolid culture medium (Methylcellulose H4034; Stem Cell Technologies), cultured for 12 days and colonies scored by light microscopy. 
ELISA and qPCR
Human or murine Gas6 levels were determined in cell culture supernatants and peripheral blood plasma using ELISA kits according to the manufacturer's instructions (R&D Systems, Wiesbaden, Germany).
Quantitative RT-PCR of human Axl was performed with cDNA from PB MNCs BCR-ABL TKI-resistant or -sensitive CML patients using premade
GeneExpression Assays from Applied Biosystems (human primers for Axl Hs01064444_m1 and GAPDH Hs99999905_m1) and the Eppendorf
MasterCycler technology (Eppendorf, Hamburg, Germany).
Western blot analysis
Western blotting was carried out as described (32 
Supplementary information
Detailed protocols are provided as Supplementary Information.
RESULTS
Axl signaling is activated in CML cell lines and patient samples
We previously discovered the role of the Gas6-Axl axis in AML, promoting proliferation of leukemia cells and establishing a chemoprotective niche, which can be abrogated by Axl-targeting approaches (27). Based on these data, we investigated whether Axl might play a role in CML pathobiology. indicating its increased activity in challenging conditions (Fig. 1B) .
Next, we quantified the levels of secreted Gas6, the main ligand of Axl, in serum samples from healthy donors and CML patients in CP and blast crisis (BC). Gas6 protein levels were measured by ELISA. The results showed that Gas6 serum levels were 2.7-fold and 8.5-fold increased in CP and BC, respectively, compared to healthy donors (healthy 1290±684 pg/mL; CP 3465±405 pg/mL; BC 10940±3868 pg/mL) (Fig. 1C) . Hence, increased amounts of Gas6 are present in the circulation of CML patients compared to healthy subjects.
Similarly, secreted Gas6 levels were quantified in the different CML cell lines in which Axl expression was previously detected, revealing that Gas6 is expressed at different levels in these cell lines (Fig. 1D ).
Thus, Axl signaling is activated in MNCs from CML patients and cell lines. Furthermore, Gas6 serum levels are increased in CML. Therefore, the Gas6-Axl axis might represent a potential therapeutic target in CML and we tested whether its genetic or pharmacological inhibition would impair CML cell survival.
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Genetic knock down of Axl inhibits CML cell growth
In order to investigate if Axl represents a therapeutic target in CML we knocked down its expression by means of shRNA in KCL-22 and K562 cells ( Supplementary Fig. S1A ). Silencing of Axl in CML cells decreased their viability compared to control transduced cells ( Fig. 2A ). Knock down of Axl inhibited phosphorylation of pStat5, pAkt and pErk, important signaling intermediates for CML survival and proliferation ( Fig. 2B and Supplementary Fig. S1A ).
BGB324 decreases viability of CML cell lines and primary CML cells
In order to investigate the therapeutic potential of pharmacologic Axl Altogether, these experiments show that Axl inhibition by BGB324 blocks proliferation and induces apoptosis of CML cells.
BGB324 does not inhibit BCR-ABL1-induced signaling
The affinity of BGB324 for Abl was 51.88 nM in biacore assays. The selectivity of BGB324 for Axl over Abl was >10-fold and >100-fold in biochemical assays and in cellular assays, respectively (33) . However, we wished to rule out that the observed biological effects might be off-target effects of BGB324 via inhibition of BCR-ABL1. In order to address this question KCL- Moreover, Axl expression was evaluated in samples of CP CML patients after 6 months of therapy with imatinib or nilotinib. Patient samples were grouped depending on whether they were responding according to ELN guidelines (34) . In concordance with the results observed before, Axl mRNA levels were higher in PB MNCs derived from BCR-ABL TKI-resistant patients compared to those that were BCR-ABL TKI-sensitive (n=17/20) (Fig. 3D ).
Altogether the data show that upregulation of Axl might be involved in resistance towards BCR-ABL TKI in CML.
Blockade of Axl exerts additive therapeutic effects with imatinib in CML cell lines
In a next step, we wished to determine the efficacy of simultaneous inhibition of Axl and BCR-ABL1 in impairing viability of CML cells. Concomitant inhibition of Axl by BGB324 (1.5 μM) and BCR-ABL1 by imatinib (500 nM) both used at their IC 50 dose level resulted in an additive effect on growth inhibition upon combined treatment (Fig. 3E ).
Moreover, to clarify which signaling pathways are involved in the biological effects observed after the combined therapy, key mediators potentially affected by both Axl-and BCR-ABL1-induced pathways were investigated. An additive effect of inhibition of Stat5 phosphorylation was detected when imatinib and BGB324 were combined, indicating that Axl induces phosphorylation of Stat5 by BCR-ABL1 independent pathways (Fig. 3F ). An additive inhibitory effect on phosphorylation of Erk and Akt was not detected (Supplementary Fig. S5A ). Of note, we could not see an upregulation of Axl in these experiments because analysis of phosphorylation of signal transduction intermediates was performed after 3 hours, which is too early for detecting differences in protein translation.
In order to validate the efficacy of simultaneous inhibition of Axl and BCR-ABL1, shcontrol-and shAxl-transduced KCL-22 cells were treated with imatinib (500 nM) and determined their viability after 48 hours. These experiments demonstrated an additive effect of combined BCR-ABL1-and Axl blockade ( Thus, Axl could be a therapeutic target in BCR-ABL TKI-resistant CML. Fig. S6A and B) . Thus, also in T315I-mutated cells BGB324 does not inhibit BCR-ABL1-induced signaling.
Subsequently, proliferation and apoptosis assays were carried out.
BaF3/T315I, KCL-22 T315I and KCL-22 PonR cells were incubated with 1.5 μM of BGB324 for 24 h and BrdU and Annexin V assays were performed. We found that BGB324 inhibited proliferation in all the three cell lines studied. In addition, BGB324 exerted a pro-apoptotic effect on the BCR-ABL TKI-resistant cell lines
shown by increased number of Annexin V + cells upon treatment (Fig. 4E and F and Supplementary Fig. S3A ). Thus, similar to BCR-ABL1-unmutated cells BGB324 reduces proliferation and induces apoptosis in BCR-ABL1-T315I mutated and ponatinib-resistant cell lines.
BGB324 induces apoptosis of BCR-ABL1 T315I mutated and BCR-ABL
TKI-resistant primary CML cells. Fig. S7A ). In line with the previous results, BGB324 was able to significantly induce apoptosis in cells from all the three 19 studied patients (Fig. 4I-K and Supplementary Fig. S8A ). Therefore, BGB324
blocked growth of colonies and induced apoptosis of BCR-ABL1 T315I-mutated and BCR-ABL TKI-resistant (including ponatinib) primary cells.
Altogether, our data indicate that BGB324 inhibits also CML cells that are resistant against current therapy including ponatinib.
BGB324 inhibits T315I-mutated CML in vivo.
With the evidence that Axl inhibition by BGB324 showed therapeutic potential in drug-resistant CML in vitro, we proceeded to investigate its effects in vivo. For this purpose two approaches were adopted. In a first step ectopic models were used, whereby murine BaF3/p210 and BaF3/T315I cells were (Fig. 5G) . Thus, diminished Erk phosphorylation by BGB324 could explain the observed reduced proliferation of CML cells in vivo.
Axl blockade exerts therapeutic effects in human BCR-ABL TKIresistant CML in vivo.
In a next step, we determined whether treatment with BGB324 could also reduce tumor growth of BCR-ABL TKI-resistant human CML cells. Therefore, T315I-mutated and KCL-22 PonR cells were injected subcutaneously into NSG mice and treated by BGB324 or control. These experiments showed a significant tumor growth inhibition upon treatment with BGB324 compared to control treatment in both models, leading to 65% and 58% regression of tumor volume of KCL-22 T315I and KCL-22 PonR tumors, respectively ( Fig. 6A and   B ).
Subsequently, to determine whether reduced proliferation might be responsible for decreased growth of BCR-ABL1 T315I-mutated and PonR tumors upon treatment with BGB324, cell proliferation was quantified by pHH3
analysis. The results indicated reduced proliferation of BGB324-treated KCL-22 21 T315I and KCL-22 PonR tumor cells compared to controls (Fig. 6C-F) .
Furthermore, in concordance with the previous results and with our in vitro data, Axl phosphorylation was decreased in BGB324-treated tumors. In addition, we found that pErk was significantly reduced in lysates from tumor tissues after treatment with BGB324 (Fig. 6G ).
BGB324 prolongs survival in a Ponatinib-resistant systemic mouse model
In addition to the ectopic models we also investigated the therapeutic effect of BGB324 in a systemic model. For the second in vivo approach, the human KCL-22 PonR cells were intravenously injected into sub-lethally irradiated NSG mice (36) . Three days later, mice were divided in two groups and treated with placebo or 25 mg/kg BGB324 as described previously. In this aggressive model, treatment with BGB324 resulted in significant prolongation of overall survival by 7 days (Fig. 6H) .
Altogether, BGB324 inhibits ABL TKI-resistant and -sensitive CML in vitro and in vivo independent of BCR-ABL1 mutational status.
DISCUSSION
BCR-ABL TKI have revolutionized CML treatment, but primary and acquired resistance as well as their toxicity continue to pose significant clinical challenges. Thus, there is the necessity of searching for new targets and personalized therapies (16, 37, 38) . In addition, our data indicate that BGB324 is active in BCR-ABL TKIresistant CML cells and mouse models, including T315I-mutated and ponatinibresistant systemic mouse models and primary cells. Especially in patients harbouring the T315I gatekeeper mutation and in ponatinib-resistant CML novel treatment options are warranted. Our data show that BGB324 is active in CML resistant to all approved treatments which is consistent with the role of Axl in promoting drug resistance in different cancers (41) . Importantly, we also demonstrate that there is a therapeutic window for the drug, because the effect 23 of BGB324 on survival and colony growth is much less pronounced in healthy CD34 + stem cells compared to CML cells. These data show that there is a therapeutic window for the drug. This conclusion is also supported by our experience in the AML trial BGB324 where the treatment has been overall welltolerated in 25 patients (28).
We also observed an inhibitory effect of BGB324 on BV-173 cells, which resemble ALL (acute lymphocytic leukemia) cells (42) , suggesting a therapeutic benefit of BGB324 in this subgroup of ALL carrying the Ph chromosome.
Nevertheless, further studies are necessary to elucidate the therapeutic potential of BGB324 in BCR-ABL1 + ALL.
Upon investigation of important signal transduction pathways
promoting CML growth and survival, pronounced reduction of phosphorylated MAPK, Stat5 and Akt were found after Axl inhibition. Previous data showed that selectivity of BGB324 (formerly known as R428) over ABL was <10-fold in biochemical assays and >100-fold higher affinity for Axl versus ABL in cellular assays (33) . Biochemical biacore data indicate that BGB324 has higher affinity to mutated BCR-ABL1 including T315I, M351T and E255K mutations (43) . Recently, an allosteric inhibitor of BCR-ABL1 (ABL001) was discovered, which in contrast to the approved BCR-ABL TKI does not bind to the ATP site of the kinase domain but induces negative regulation of the kinase activity by an allosteric mechanism (46) . Thereby, emergence of resistance due to mutations in the ATP site can be circumvented in preclinical models. ABL001 is currently being investigated in a Phase 1 study. The mechanism of action of ABL001 is distinct from BGB324, thus it might be interesting to combine both drugs.
However, further studies are necessary to investigate this combinatory approach.
Interestingly, higher levels of Axl expression were found after imatinib per milliliter (pg/ml) from three replicates. *P < 0.05, **P < 0.01 and ***P < 0.001 duplicates) (J and K). *P < 0.05, **P < 0.01 and ***P < 0.001 (student's t-test). normalized to control-treated tumors (n=4/7) and represented as %. *P < 0.05, **P < 0.01 and ***P < 0.001. 
